Singlera Genomics, Astellas Pharma Partner to Study Drug Reactions
The collaborators will design assays using Singlera's methylation-based mTitan platform for monitoring biological responses to drug treatment.
FLT3 Inhibitor Treatment Improves Survival in Relapsed, Refractory AML Patients With Mutations
Results from the phase 3 ADMIRAL trial were announced during the American Association for Cancer Research annual meeting.
Invivoscribe CDx Assay Gets Expanded FDA Approval Alongside Astellas AML Drug
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based test for internal tandem duplications and tyrosine kinase domain mutations D835 and I836 in the FLT3 gene.
Astellas to Use GenomeDx Prostate Cancer Classifier, Database in Drug Study
GenomeDx will use its Decipher Classifier and Genomics Resource Information Database to analyze samples, for tumor aggressiveness, and identify predictive signatures.
Courtagen, Astellas Partner on Mitochondrial Disease Drug Development
Courtagen will use its ZiPhyr bioinformatics pipeline to help Astellas develop a predictive model that can be used in early-stage drug development.